Search results
Results from the WOW.Com Content Network
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
But it could become a modest one, the same way it is for the pharma companies. Recursion currently has $50.1 million in debt and capital lease obligations, while Viking has a scant $1.1 million.
For premium support please call: 800-290-4726 more ways to reach us
TOKYO (Reuters) -U.S. private equity firm Bain Capital is set to raise its offer price for Japan's Fuji Soft to 9,600 yen ($63.35) per share, the Nikkei newspaper reported on W… Associated Press ...
The successful prediction of a stock's future price could yield significant profit. The efficient market hypothesis suggests that stock prices reflect all currently available information and any price changes that are not based on newly revealed information thus are inherently unpredictable. Others disagree and those with this viewpoint possess ...
In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company. [6] On 22 March 2012, the company's shares were re-listed on the NYSE. In 2013, Sun Pharmaceuticals attempted to buy the remaining shares in the company (it owns 69% stake), but as the company's financial performance improved, shareholders rejected the offer and the company remained publicly listed.
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]
Pharma companies have announced price hikes of 10% or more on a dozen drugs and another two dozen-plus raised their prices by 9.9% in January. Many of these pricey new drugs are fairly obscure ...